Edgewise Therapeutics, Inc. (EWTX): R&D Expense
$151.39M
Year ended 2025-12-31
$171.27M
Trailing 12 months to 2026-06-30
+41.0%
3-year compound annual growth
+58.8%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $151.39M | +19.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $126.97M | +39.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $90.91M | +68.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $54.03M | +67.9% | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | $32.19M | +114.8% | 2023-02-23, From 2021-01-01 |
| 2020-12-31 | $14.98M | n/a | 2022-02-24, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $151.39M | +19.2% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $25.99M | -9.9% |
| Geron Corp (GERN) | 2025-12-31 | $71.43M | -31.1% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $157.70M | +26.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $33.30M | +42.4% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $115.11M | +16.1% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $94.79M | +55.6% |
Compare EWTX, LAB, GERN, OLMA side by side · Screen every company in Pharmaceutical Preparations ↗